Amod Sarnaik, M.D.
H. Lee Moffitt Cancer Center and Research Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Amod Sarnaik, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:27 UTC. Open this list on ClinicalTrials.gov
- Early Ph1NCT02652455 · Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic MelanomaH. Lee Moffitt Cancer Center and Research Institute · completed · Melanoma (Skin), Skin Cancer · principal investigator
- N/ANCT01701674 · Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets PtsH. Lee Moffitt Cancer Center and Research Institute · completed · Metastatic Melanoma · principal investigator
- Ph2NCT01659151 · Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic MelanomaH. Lee Moffitt Cancer Center and Research Institute · completed · Metastatic Melanoma · principal investigator
- N/ANCT01005745 · Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic MelanomaH. Lee Moffitt Cancer Center and Research Institute · completed · Metastatic Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:27 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.